NEW YORK (GenomeWeb) – Elucidata, a startup developer of analytics software to support drug discovery, announced today that it has raised $1.7 million in seed funding.

Hyperplane Venture Capital led the seed round, with participation from unspecified angel investors. The company said it would use the money to expand at its twin headquarters in Cambridge, Massachusetts, and in New Delhi, India. Elucidata said that it has already become profitable despite only being bootstrapped up to this point.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.